Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples